Postoperative tolvaptan use in left ventricular assist device patients: The TOLVAD randomized pilot study.

ABSTRACT:

Purpose

Tolvaptan, a selective vasopressin type-2 antagonist, has been shown to increase serum sodium (Na) and urine output in hyponatremic left ventricular assist device (LVAD) patients in retrospective studies. In this prospective randomized pilot study, we aimed to assess the efficacy of tolvaptan in this population.

Methods

We conducted a prospective, randomized, non-blinded pilot study of LVAD recipients with post-operative hyponatremia (Na < 135 mEq/L) (NCT05408104). Eligible participants were randomized to receive tolvaptan 15 mg daily in addition to usual care versus usual care alone. The primary outcome was a change in Na level and estimated glomerular filtration rate (eGFR), from the first post-operative day of hyponatremia (the day of randomization) to discharge.<

SUBMITTER: Belkin MN 

PROVIDER: S-EPMC10227625 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature